MSACL 2018 US Abstract

Topic: Small Molecules / Tox

A Sensitive Method for the Simultaneous UHPLC-MS/MS Analysis of Milrinone and Dobutamine in Blood Plasma Using NH4F as the Eluent Additive

Ruta Veigure (Presenter)
University of Tartu

Bio: Ruta has obtained bachelor’s degree in chemistry from University of Latvia. She has graduated from the University of Tartu (first in class), obtaining a Master’s degree in Science of Engineering. Currently Ruta is a full-time chemistry PhD student in University of Tartu with her research focused on novel LC-MS eluent additives.

Authorship: Kalev Takkis (1) Ruta Veigure (1), Tuuli Metsvaht (2), Maarja Hallik (3,4), Mari-Liis Ilmoja (4), Joel Starkopf (3,5), Karin Kipper (1,6,7)
(1) University of Tartu, Institute of Chemistry, 14a Ravila Street, 50411 Tartu, Estonia (2) Tartu University Hospital, Lunini 6, 51014 Tartu Estonia (3) Department of Anaesthesiology and Intensive Care, Tartu University Hospital, Tartu (4) Department of Anaesthesiology and Intensive Care, Tallinn Children's Hospital, Tallinn, Estonia (5) Clinic of Anaesthesiology an Intensive Care, Tartu University Hospital, Tartu, Estonia (6) Paediatric Infectious Diseases Research Group, Institute for Infection and Immunity, St. George's, University of London, Cranmer Terrace, London, SW17 0RE, United Kingdom (7) Analytical Services International, St George’s University of London, Cranmer Terrace, London, SW17 0RE, United Kingdom

Short Abstract

The content of this abstract has been temporarily embargoed.

Long Abstract

This content of this abstract has been temporarily embargoed.


References & Acknowledgements:

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript, apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

1. Feneck R (2007) Phosphodiesterase inhibitors and the cardiovascular system. Contin Educ Anaesthesia, Crit Care Pain 7:203–207. doi: 10.1093/bjaceaccp/mkm039

2. Samiee-Zafarghandy S, Raman SR, van den Anker JN, McHutchison K, Hornik CP, Clark RH, Brian Smith P (2015) Safety of milrinone use in neonatal intensive care units. Early Hum Dev 91:31–35. doi: 10.1016/j.earlhumdev.2014.10.007

3. Majerus TC, Dasta JF, Bauman JL, Danziger LH, Ruffolo RR (1989) Dobutamine: Ten Years Later. Pharmacother J Hum Pharmacol Drug Ther 9:245–259. doi: 10.1002/j.1875-9114.1989.tb04133.x

4. Takkis K, Aro R, Kõrgvee L-T, Varendi H, Lass J, Herodes K, Kipper K (2017) Signal Enhancement in the HPLC-ESI-MS/MS analysis of spironolactone and its metabolites using HFIP and NH4F as eluent additives. Anal Bioanal Chem 409:3145–3151. doi: 10.1007/s00216-017-0255-4

5. Committee for Medicinal Products for Human Use (CHMP) (2011) European Medicines Agency (EMA) guideline on bioanalytical method validation. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf. Accessed 1 May 2016

6. Bhatt-Mehta V, Nahata MC (1989) Dopamine and dobutamine in pediatric therapy. Pharmacotherapy 9:303–14.

7. Lindsay CA, Barton P, Lawless S, Kitchen L, Zorka A, Garcia J, Kouatli A, Giroir B (1998) Pharmacokinetics and pharmacodynamics of milrinone lactate in pediatric patients with septic shock. J Pediatr 132:329–34.

8. Albóniga OE, Alonso ML, Blanco ME, González O, Grisal Na A, Campanero MA, Alonso RM (2017) Quantitative determination of dobutamine in newborn pig plasma samples by HPLC–MS/MS. J Pharm Biomed Anal J Pharm Biomed 145:178–185. doi: 10.1016/j.jpba.2017.06.050

9. Rajaram S, Deepthi Vemuri V, Natham R (2014) Ascorbic acid improves stability and pharmacokinetics of rifampicin in the presence of isoniazid. J Pharm Biomed Anal 100:103–108. doi: 10.1016/j.jpba.2014.07.027

10. Melo LP, Queiroz RHC, Queiroz MEC (2011) Automated determination of rifampicin in plasma samples by in-tube solid-phase microextraction coupled with liquid chromatography. J Chromatogr B 879:2454–2458. doi: 10.1016/j.jchromb.2011.06.041


Financial Disclosure

DescriptionY/NSource
Grantsno
Salaryno
Board Memberno
Stockno
Expensesno

IP Royalty: no

Planning to mention or discuss specific products or technology of the company(ies) listed above:

no